U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C15H24N2O2
Molecular Weight 264.3633
Optical Activity UNSPECIFIED
Defined Stereocenters 5 / 5
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of OXYMATRINE

SMILES

[H][C@]12CCC[N@@+]3([O-])CCC[C@]([H])([C@@]4([H])CCCC(=O)N4C1)[C@]23[H]

InChI

InChIKey=XVPBINOPNYFXID-JARXUMMXSA-N
InChI=1S/C15H24N2O2/c18-14-7-1-6-13-12-5-3-9-17(19)8-2-4-11(15(12)17)10-16(13)14/h11-13,15H,1-10H2/t11-,12+,13+,15-,17+/m0/s1

HIDE SMILES / InChI

Molecular Formula C15H24N2O2
Molecular Weight 264.3633
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry EPIMERIC
Additional Stereochemistry No
Defined Stereocenters 4 / 5
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Oxymatrine is one of the key components extracted from Sophora flavescens, a leguminous plant grown in China, Japan, and some European countries. It has attracted much attention because of its low toxicity and side effects. Extensive research over the past decades have revealed various important pharmacological activities of oxymatrine under in vitro and in vivo conditions, including anti-inflammation, immunoregulatory, antihepatitis virus infection, antihepatic fibrosis, antianaphylaxis, and other immune regulation. Oxymatrine has been extensively studied for their cancer chemopreventive potential against various cancers, for instance, human pancreatic cancer, gastric cancer, breast cancer, lung cancer, osteosarcoma, and leukemia. However, the precise mechanisms underlying the anticancer activity of oxymatrine are largely unknown.

CNS Activity

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
513.0 µM [IC50]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Secondary
Unknown

PubMed

Sample Use Guides

In Vivo Use Guide
Therapeutic doses of the substantially pure oxymatrine are administered twice daily at a dose of between about 5 mg and about 500 mg per administration
Route of Administration: Oral
In Vitro Use Guide
Human hepatome call lines Hep-G2 and SMMC-7721 were incubated with oxymatrine at concentrations 0.25 to 2.5 mg/ml for 24 to 48 hours, and was found that the growth and proliferation of hepatoma cells decreased in a time-dependent manner.
Substance Class Chemical
Record UNII
85U4C366QS
Record Status Validated (UNII)
Record Version